Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 396

Results For "CE"

9359 News Found

Sharp develops Plasmacluster tech that reduces airborne novel coronavirus
Drug Approval | September 07, 2021

Sharp develops Plasmacluster tech that reduces airborne novel coronavirus

Plasmacluster technology significantly inactivates SARS-CoV-2 contained in adherent saliva in an environment with 60% humidity where the physiological protective function is maintained


ABB’s ACS360 Drives enhance safety and energy efficiency at Bharat Biotech’s Covaxin plant
Biotech | September 07, 2021

ABB’s ACS360 Drives enhance safety and energy efficiency at Bharat Biotech’s Covaxin plant

ABB Drives play a key role in the cleanroom infrastructure of Bharat Biotech, India’s first indigenous Covid-19 vaccine manufacturer. The drives are easy to commission, use and ensure higher energy efficiency


Zydus Cadila’s Sitagliptin base tablets receive tentative approval from US FDA
Drug Approval | September 06, 2021

Zydus Cadila’s Sitagliptin base tablets receive tentative approval from US FDA

Zydus’ Sitagliptin base contains the active moiety Sitagliptin in a different form than used in the branded reference product, Januvia (Sitagliptin Phosphate)


Alembic JV Aleor receives US FDA final approval for skin disorder gel
Drug Approval | September 06, 2021

Alembic JV Aleor receives US FDA final approval for skin disorder gel

Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea


TB Alliance partners with Lupin for non-exclusive anti-TB drug
Policy | September 06, 2021

TB Alliance partners with Lupin for non-exclusive anti-TB drug

According to WHO, over 1.5 million people died of TB in 2020


Govt revises NLEM and slashes prices of 39 drugs
Policy | September 04, 2021

Govt revises NLEM and slashes prices of 39 drugs

At present 18 per cent of the local pharmaceutical market is under government's price control


Reliance Strategic Business Ventures acquires Strand Life Sciences for Rs 393 crores
Drug Approval | September 04, 2021

Reliance Strategic Business Ventures acquires Strand Life Sciences for Rs 393 crores

The investment is part of the group's digital health initiatives, to foster affordable access to world-class technology and an innovation-led healthcare ecosystem in India


Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent
Drug Approval | September 04, 2021

Dr Reddy’s enters agreement with Citius to sell rights of its anti-cancer agent

In March 2016, Dr. Reddy’s had acquired the exclusive global rights (excluding Japan and Asia) to the investigational anti-cancer agent E7777 from Eisai Co.


HCG acquires oncology labs and divests stake in Strand Life Sciences
Healthcare | September 04, 2021

HCG acquires oncology labs and divests stake in Strand Life Sciences

The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business


Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine
Drug Approval | September 04, 2021

Reliance Life Science gets go-ahead for Phase I clinical trial for Covid-19 vaccine

The trial will be conducted across eight sites in Maharashtra